DCM
TMBR

DAFNA Capital Management’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

DAFNA Capital Management’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-8
Closed -$58K – 82
2017
Q1 		$58K Buy
8
+3
+60% +$20.8K 0.05% 71
2016
Q4 		$29K Buy
+5
New +$25.6K 0.03% 65
2016
Q2 		– Sell
-10
Closed -$160K – 105
2016
Q1 		$160K Buy
+10
New +$226K 0.14% 81

Other funds holding TMBR

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

DAFNA Capital Management's TMBR Position: Q2 2017 in Review

DAFNA Capital Management sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q2 2017, closing a stake of 8 shares — an estimated $58K sold.

DAFNA Capital Management first reported a position in TMBR in Q1 2016 and held it in 3 quarters. The position peaked at $160K in Q1 2016. 17 funds tracked by Wall St. Rank hold TMBR as of Q2 2017.

  • DAFNA Capital Management reported no remaining Timber Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • DAFNA Capital Management sold 8 Timber Pharmaceuticals, Inc. shares in Q2 2017, an estimated $58K.
  • DAFNA Capital Management first reported a position in Timber Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • DAFNA Capital Management's Timber Pharmaceuticals, Inc. position peaked at $160K in Q1 2016.
  • 17 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q2 2017.

Based on DAFNA Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.